BDR Group of companies has grown steadily and become a house-hold name in the pharmaceutical Industry over the last 15 years, in both domestic and international arenas. We are recognized as a niche player in manufacturing of Pharmaceutical APIs and for our renowned new age formulations. The group is complemented majorly by its two companies - BDR Pharmaceuticals International Pvt Ltd and BDR Life   sciences Pvt. Ltd, each one having stamped its own supremacy in respective fields, i.e. API and formulation manufacturing, respectively.

Walk in Drive

With over three decades of leadership in pharmaceutical innovation and quality, Baroque Pharmaceuticals has evolved into a premier backend global partner. From formulation R&D to large-scale commercial manufacturing, we offer end-to- end solutions tailored to meet the dynamic needs of global healthcare markets.

Baroque Pharmaceuticals Pvt. Ltd. — Walk-In Interview

The Ministry of Health and Family Welfare has issued an advisory to States and Union Territories regarding the regulation of stem cell therapy, reiterating that stem cell treatments can be offered as standard clinical care only for approved disease conditions and indications. The advisory was issued on September 16, 2026, in the context of the Supreme Court judgment dated January 30, 2026, in Yash Charitable Trust & Ors. v. Union of India & Ors.